Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane
Authors:
- 30 January 2009
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 64 (4) , 837-845
Abstract
Purpose The objective of the current investigation is to determine whether non-toxic doses of the catalytic topoisomerase-II inhibitor, dexrazoxane, have influence on the genomic damage induced by the anticancer topoisomerase-II poison, etoposide, on mice bone marrow cells. Method The scoring of micronuclei, chromosomal aberrations, and mitotic activity were undertaken as markers of cyto- and genotoxicity. Oxidative damage markers such as reduced glutathione and lipid peroxidation were assessed as a possible mechanism underlying this amelioration. Results Dexrazoxane pre-treatment significantly reduced the etoposide-induced micronuclei formation, chromosomal aberrations, and also the suppression of erythroblast proliferation in bone marrow cells of mice. These effects were dose dependent. Etoposide induced marked biochemical alterations characteristic of oxidative stress including enhanced lipid peroxidation and reduction in the reduced glutathione level. Prior administration of dexrazoxane ahead of etoposide challenge ameliorated these biochemical markers. Conclusion Based on our data presented, strategies can be developed to decrease the etoposide-induced genomic damage in normal cells using dexrazoxane.Keywords
This publication has 38 references indexed in Scilit:
- Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in ratsBritish Journal of Pharmacology, 2007
- Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycinBritish Journal of Pharmacology, 2006
- Combining Etoposide and Dexrazoxane Synergizes with Radiotherapy and Improves Survival in Mice with Central Nervous System TumorsClinical Cancer Research, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Cytogenetic risk assessment of etoposide from mouse bone marrowJournal of Applied Toxicology, 2004
- The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel reviewJournal of Cancer Research and Clinical Oncology, 2003
- Catalytic inhibitors of topoisomerase II are DNA‐damaging agents: induction of chromosomal damage by merbarone and ICRF‐187Environmental and Molecular Mutagenesis, 2002
- The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cellsAnti-Cancer Drugs, 1996
- potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: Comparison to salmonella responsesEnvironmental and Molecular Mutagenesis, 1994
- Etoposide (VP‐16): Cytogenetic studies in miceEnvironmental and Molecular Mutagenesis, 1994